These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

909 related articles for article (PubMed ID: 25993145)

  • 1. Managing immune checkpoint-blocking antibody side effects.
    Postow MA
    Am Soc Clin Oncol Educ Book; 2015; ():76-83. PubMed ID: 25993145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Blockade in Cancer Therapy.
    Postow MA; Callahan MK; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis.
    Reddy HG; Schneider BJ; Tai AW
    Clin Transl Gastroenterol; 2018 Sep; 9(9):180. PubMed ID: 30228268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
    Hofmann L; Forschner A; Loquai C; Goldinger SM; Zimmer L; Ugurel S; Schmidgen MI; Gutzmer R; Utikal JS; Göppner D; Hassel JC; Meier F; Tietze JK; Thomas I; Weishaupt C; Leverkus M; Wahl R; Dietrich U; Garbe C; Kirchberger MC; Eigentler T; Berking C; Gesierich A; Krackhardt AM; Schadendorf D; Schuler G; Dummer R; Heinzerling LM
    Eur J Cancer; 2016 Jun; 60():190-209. PubMed ID: 27085692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
    Papouin B; Mussini C; De Martin E; Guettier C
    Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Managing the Adverse Effects Related to Immune Checkpoint Inhibitors].
    Kuo HH; Chen WW
    Hu Li Za Zhi; 2018 Jun; 65(3):88-95. PubMed ID: 29790143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
    Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
    Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.
    Azoury SC; Straughan DM; Shukla V
    Curr Cancer Drug Targets; 2015; 15(6):452-62. PubMed ID: 26282545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
    Pollack MH; Betof A; Dearden H; Rapazzo K; Valentine I; Brohl AS; Ancell KK; Long GV; Menzies AM; Eroglu Z; Johnson DB; Shoushtari AN
    Ann Oncol; 2018 Jan; 29(1):250-255. PubMed ID: 29045547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.
    Friedman CF; Proverbs-Singh TA; Postow MA
    JAMA Oncol; 2016 Oct; 2(10):1346-1353. PubMed ID: 27367787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing adverse effects of immunotherapy.
    Gerson JN; Ramamurthy C; Borghaei H
    Clin Adv Hematol Oncol; 2018 May; 16(5):364-374. PubMed ID: 29851932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
    Moreno-Cubero E; Larrubia JR
    World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.